- Avricore is a leader in the health diagnostics space offering the most sophisticated and complete solution for pharmacy today
- The company is also leading a charge aimed at saving lives and money spent on health care
- Avricore partnered with Abbott Diagnostics becoming the first third-party technology company to hold distribution agreements with the manufacturer
- Avricore is currently entering a period of epic growth
Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a health diagnostics technology innovator, is a leader in the point-of-care (“POC”) diagnostics space and a company of several firsts. Through its flagship platform and eponymous wholly owned subsidiary, HealthTab(TM), Avricore has provided a proactive approach in the fight against diseases such as prediabetes, diabetes, SARS-CoV-2 (COVID-19), Influenza A and B, strep, and RSV (
https://ibn.fm/DPsLu).
Speaking during an interview with Stuart Smith as part of a recent Bell2Bell Podcast episode (
https://ibn.fm/61OLh), AVCR CEO Hector Bremner summed up the company’s unique diagnostics and cloud-based technology by saying, “We are really excited to be leaders in the field. There’s nobody quite like us. There are people that do parts of what we do, but we have brought the most sophisticated and most complete solution for pharmacy today.”
Better known as HealthTab, the solution is a fully automated, turnkey POC testing system that combines high-quality analyzers from manufacturers such as Abbott Diagnostics and Abaxis Global Diagnostics with a cloud-based solution, creating a network that benefits pharmacies and patients alike.
For patients, the HealthTab system, through the analyzers, tests multiple key biomarkers associated with chronic and infectious diseases and subsequently generates lab-accurate, real-time results that patients can view via the system’s consumer-facing interface. For pharmacies, Bremner noted, Avricore provides an additional revenue-generating opportunity in the form of cognitive pharmacy services.
In its vanguard role, Avricore is leading a charge that involves leveraging early detection and screening to save lives as well as the amount of money spent in health care. With early diagnosis having been proven as instrumental in reducing mortality and cardiovascular morbidity resulting from Type 2 diabetes (
https://ibn.fm/7Htz0), as well as death caused by COVID-19 (
https://ibn.fm/982Ml), HealthTab is indeed a boon.
“I’ve always really believed that we need a true health care system [in Canada] that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future. We’re really passionate about leading this charge,” continued Bremner.
Avricore’s leadoff stature also came into focus when it partnered with Abbott Diagnostics as part of a distribution agreement. Bremner, who described the partnership as groundbreaking, noted that Abbott does not ordinarily do distribution agreements for their technology with third-party technology companies like AVCR.
“Normally, to distribute Abbott technologies at this level, you have to be a fairly large distributor of health care technologies to begin with. We were extremely fortunate to pioneer this agreement and really break ground to see what was possible as a value-added reseller to bring our technology in combination with theirs,” observed Bremner.
Bremner noted that the partnership accelerated Avricore’s growth, further pointing out that the company is ideally poised for a great finish to the current year and continued growth through 2023, having repaid its debts and raised about $4.5 million this year.
Avricore is committed to becoming the world’s largest health diagnostics company. With a primary focus on developing a network of POC analyzers that utilize its HealthTab software in community pharmacy, the company is staking a claim as a leader in the space.
For more information, visit the company’s website at
www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at
https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.